EGFR and colorectal cancer: The main recommendations contained in this study are the following: testing for RAS mutations as a negative predictor of response to EGFR-targeted monoclonal antibodies; BRAF mutations and MMR status for their prognostic value and as heralds of Lynch syndrome; there is no sufficient evidence to recommend the systematic mutational analysis of PI3KCA (although retrospective studies have suggested improved survival with post-operative aspirin use in patients whose colorectal cancers harbor a PI3KCA mutation) and the analysis of PTEN alterations [492].